Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial
Autors principals: | , , , , , , , , , , , , , , |
---|---|
Format: | Conference item |
Publicat: |
American Society of Hematology
2016
|